Ophthalmology is the specialty that learned to prevent blindness, then to reverse it.

In July 1981, a large American study reported on a light treatment for diabetic eye disease. Diabetes damages the small blood vessels of the retina. The eye grows new vessels to replace them, and the new vessels bleed. The study treated one eye of each patient with photocoagulation, which uses intense light to seal the retina, and left the other eye untreated. The treatment cut the risk of severe vision loss by half or more. The treatment had a price. Some treated eyes lost a little sharpness, and some lost part of their side vision. So the study set out which eyes gained more than they lost, and told doctors to treat those at once. A blinding disease now had a treatment, and rules for using it.

Twenty-one years later, in June 2002, a trial asked whether to treat glaucoma before it existed. High pressure inside the eye raises the risk of glaucoma, but nobody knew whether lowering it early helped. The trial took 1,636 people with high eye pressure and no damage yet. Half got pressure-lowering eye drops. Half were watched. After five years, 4.4% of the treated group had developed glaucoma, against 9.5% of those watched. The drops had cut the risk by more than half, before any sight was lost.

Four years after that, in October 2006, the New England Journal of Medicine published a trial in wet macular degeneration, the leading cause of blindness in older people. Abnormal vessels grow under the retina and leak, driven by a growth signal called VEGF. Ranibizumab blocks it. The trial gave 716 patients monthly injections into the eye, of ranibizumab or a sham. After a year, 94.6% on ranibizumab had kept their vision, against 62.2% on sham. And 33.8% could read three more lines on the chart, against 5.0%. Vision on sham fell by 10.4 letters on average. Vision on ranibizumab rose by 7.2. For the first time, a treatment had given sight back.

These are three of the thousands of studies that shaped modern ophthalmology. They taught ophthalmology that light could stop diabetic bleeding, that eye drops could prevent glaucoma before it started, and that an injection could restore vision, and each time the answer was in a paper years before it was in a textbook.

It is still happening. Recently, in January 2026, the New England Journal of Medicine published a study of people blinded by dry macular degeneration. More than 5 million people have it, and nothing restores the sight it takes. The study implanted a tiny photovoltaic chip under the retina of 38 of them. Glasses beam infrared light onto the chip, and the chip stimulates the retina underneath. A year later, 26 of the 32 assessed could see meaningfully better. The cost was surgery: 26 serious adverse events in 19 people, most within two months of the operation, and most resolved. For the first time, sight lost to this disease had been given back. Practice follows the literature as it goes. It is a good culture. It has exactly one cost.